ArticleEuropean journal of preventive cardiology2026
Individualizing SGLT2 inhibitors cardiovascular benefit in patients with type 2 diabetes: target trial emulation meets machine learning.
Yosef Manla et al.PubMed ↗Publisher ↗
No numbers read from the abstract.